CMMB
Chemomab Therapeutics Ltd. (NASDAQ)
Healthcare — Biotechnology
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Price History
Fundamentals
| Market Cap | $12.24M |
| P/E Ratio (TTM) | - |
| Forward P/E | -56.67 |
| EPS (TTM) | $-1.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -70.61% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $15.00 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.2 |
| Beta | 0.61 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $4.92 |
| 52-Week Low | $1.35 |
| 50-Day Avg | $1.69 |
| 200-Day Avg | $2.06 |
| Avg Volume | 43.5K |
| Volume | 62.1K |
Performance Analysis
BULLISHCMMB shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report